{"id":996,"date":"2023-09-01T17:58:55","date_gmt":"2023-09-01T17:58:55","guid":{"rendered":"https:\/\/clinicamaddarena.com.br\/?p=996"},"modified":"2023-10-08T07:22:10","modified_gmt":"2023-10-08T07:22:10","slug":"pregabalin-uses-interactions-mechanism-of-action-70","status":"publish","type":"post","link":"https:\/\/clinicamaddarena.com.br\/blog\/pregabalin-uses-interactions-mechanism-of-action-70\/","title":{"rendered":"Pregabalin: Uses, Interactions, Mechanism of Action DrugBank Online"},"content":{"rendered":"
In this study, 105 patients received LYRICA and 70 patients received placebo for up to 14 days. Approximately 2.5% of patients receiving LYRICA and no patients receiving placebo in trials of adjunctive therapy for partial-onset seizures discontinued prematurely due to adverse reactions. In the LYRICA treatment group, the adverse reactions leading to discontinuation were somnolence (3 patients), worsening of epilepsy (1 patient), and hallucination (1 patient).<\/p>\n
Following repeated administration, steady state is achieved within 24 to 48 hours. Multiple-dose pharmacokinetics can be predicted from single-dose data. Prospectively planned ophthalmologic testing, including visual acuity testing, formal visual field testing and dilated funduscopic examination, was performed in over 3600 patients. In these patients, visual acuity was reduced in 7% of patients treated with LYRICA, and 5% of placebo-treated patients. Visual field changes were detected in 13% of LYRICA-treated, and 12% of placebo-treated patients. Funduscopic changes were observed in 2% of LYRICA-treated and 2% of placebo-treated patients.<\/p>\n
Instruct patients to discontinue LYRICA and immediately seek medical care if they experience these symptoms [see WARNINGS AND PRECAUTIONS]. As the thiazolidinedione class of antidiabetic drugs can cause weight gain and\/or fluid retention, possibly exacerbating or leading to heart failure, exercise caution when co-administering LYRICA and these agents. There have been postmarketing reports of angioedema in patients during initial and chronic treatment with LYRICA. Specific symptoms included swelling of the face, mouth (tongue, lips, and gums), and neck (throat and larynx).<\/p>\n
Pregabalin is in a class of medications called anticonvulsants. It works by decreasing the number of pain signals that are sent out by damaged nerves in the body. The efficacy of LYRICA as adjunctive therapy for partial-onset seizures in adult patients was established in three 12-week, randomized, double-blind, placebo-controlled, multicenter studies.<\/p>\n
Some of the most common side effects of LYRICA CR are dizziness, blurry vision, weight gain, sleepiness, tiredness, swelling of hands and feet, dry mouth, and nausea. LYRICA and LYRICA CR may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. If you have suicidal thoughts or actions, do not stop LYRICA or LYRICA CR without first talking to your doctor. LYRICA may cause swelling of your hands, legs, and feet, which can be serious for people with heart problems. You should not drive or work with machines until you know how LYRICA affects you. Also, tell your doctor right away about muscle pain or problems along with feeling sick and feverish, or any changes in your eyesight, including blurry vision or if you have any kidney problems or get dialysis.<\/p>\n
Pregabalin for Multiple Sclerosis.<\/p>\n